Multi-Omics Profiling to Assess Signaling Changes Upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Feb 15

PMID 35159281

Authors

Xuechun Wang

Jin Hu

Yihao Fang

Yanbin Fu

Bing Liu

Chao Zhang

Shan Feng

Xin Lu

Affiliations

Soon will be listed here.

Abstract

The inactivation of von Hippel-Lindau (VHL) is critical for clear cell renal cell carcinoma (ccRCC) and VHL syndrome. VHL loss leads to the stabilization of hypoxia-inducible factor α (HIFα) and other substrate proteins, which, together, drive various tumor-promoting pathways. There is inadequate molecular characterization of VHL restoration in VHL-defective ccRCC cells. The identities of HIF-independent VHL substrates remain elusive. We reinstalled VHL expression in 786-O and performed transcriptome, proteome and ubiquitome profiling to assess the molecular impact. The transcriptome and proteome analysis revealed that VHL restoration caused the downregulation of hypoxia signaling, glycolysis, E2F targets, and mTORC1 signaling, and the upregulation of fatty acid metabolism. Proteome and ubiquitome co-analysis, together with the ccRCC CPTAC data, enlisted 57 proteins that were ubiquitinated and downregulated by VHL restoration and upregulated in human ccRCC. Among them, we confirmed the reduction of TGFBI (ubiquitinated at K676) and NFKB2 (ubiquitinated at K72 and K741) by VHL re-expression in 786-O. Immunoprecipitation assay showed the physical interaction between VHL and NFKB2. K72 of NFKB2 affected NFKB2 stability in a VHL-dependent manner. Taken together, our study generates a comprehensive molecular catalog of a VHL-restored 786-O model and provides a list of putative VHL-dependent ubiquitination substrates, including TGFBI and NFKB2, for future investigation.

Citing Articles

In Silico Exploration of AHR-HIF Pathway Interplay: Implications for Therapeutic Targeting in ccRCC.

Gregoris F, Minervini G, Tosatto S Genes (Basel). 2024; 15(9).

PMID: 39336758 PMC: 11431742. DOI: 10.3390/genes15091167.

HOOK1 Inhibits the Progression of Renal Cell Carcinoma via TGF-β and TNFSF13B/VEGF-A Axis.

Yin L, Li W, Chen X, Wang R, Zhang T, Meng J Adv Sci (Weinh). 2023; 10(17):e2206955.

PMID: 37085921 PMC: 10265082. DOI: 10.1002/advs.202206955.

Integrative analysis of transcriptomic landscape and urinary signature reveals prognostic biomarkers for clear cell renal cell carcinoma.

Zhang W, Liu W, Yang Y, Xiao C, Xiao Y, Tan X Front Oncol. 2023; 13:1102623.

PMID: 37035174 PMC: 10079990. DOI: 10.3389/fonc.2023.1102623.

Research Progress of Tumor Microenvironment Targeted Therapy for Clear Cell Renal Cell Carcinoma.

Huang Y, Sun H, Guo P Cancer Control. 2023; 30:10732748231155700.

PMID: 36772805 PMC: 9926375. DOI: 10.1177/10732748231155700.

Tumor hypoxia: From basic knowledge to therapeutic implications.

Liao C, Liu X, Zhang C, Zhang Q Semin Cancer Biol. 2023; 88:172-186.

PMID: 36603793 PMC: 9929926. DOI: 10.1016/j.semcancer.2022.12.011.

References

Choueiri T, Bauer T, Papadopoulos K, Plimack E, Merchan J, Mcdermott D . Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021; 27(5):802-805. PMC: 9128828. DOI: 10.1038/s41591-021-01324-7. View

Cho H, Du X, Rizzi J, Liberzon E, Chakraborty A, Gao W . On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 2016; 539(7627):107-111. PMC: 5499381. DOI: 10.1038/nature19795. View

Huang T, Cheng X, Chahoud J, Sarhan A, Tamboli P, Rao P . Effective combinatorial immunotherapy for penile squamous cell carcinoma. Nat Commun. 2020; 11(1):2124. PMC: 7195486. DOI: 10.1038/s41467-020-15980-9. View

Shang D, Liu Y, Yang P, Chen Y, Tian Y . TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology. 2012; 79(4):966.e1-7. DOI: 10.1016/j.urology.2011.12.011. View

Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T . A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. 2004; 31(5):740-51. DOI: 10.1007/s00259-003-1441-5. View

Islam M, Xu Y, Tao W, Ubellacker J, Lim M, Aum D . Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng. 2019; 2(11):850-864. PMC: 6486184. DOI: 10.1038/s41551-018-0284-0. View

Lebdai S, Verhoest G, Parikh H, Jacquet S, Bensalah K, Chautard D . Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma. Urol Oncol. 2014; 33(2):69.e11-8. DOI: 10.1016/j.urolonc.2014.06.005. View

Ho Sui S, Mortimer J, Arenillas D, Brumm J, Walsh C, Kennedy B . oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 2005; 33(10):3154-64. PMC: 1142402. DOI: 10.1093/nar/gki624. View

Gossage L, Eisen T, Maher E . VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2014; 15(1):55-64. DOI: 10.1038/nrc3844. View

10.

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

11.

Bertout J, Majmundar A, Gordan J, Lam J, Ditsworth D, Keith B . HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A. 2009; 106(34):14391-6. PMC: 2726037. DOI: 10.1073/pnas.0907357106. View

12.

Park H, Kim H, Kim H, Yoo Y, Shin H, Choi E . Acetylated K676 TGFBIp as a severity diagnostic blood biomarker for SARS-CoV-2 pneumonia. Sci Adv. 2020; 6(31). PMC: 10715714. DOI: 10.1126/sciadv.abc1564. View

13.

Schokrpur S, Hu J, Moughon D, Liu P, Lin L, Hermann K . CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma. Sci Rep. 2016; 6:29032. PMC: 4928183. DOI: 10.1038/srep29032. View

14.

Du W, Zhang L, Brett-Morris A, Aguila B, Kerner J, Hoppel C . HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism. Nat Commun. 2017; 8(1):1769. PMC: 5701259. DOI: 10.1038/s41467-017-01965-8. View

15.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

16.

Liu X, Simon J, Xie H, Hu L, Wang J, Zurlo G . Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. Mol Cell. 2020; 77(6):1294-1306.e5. PMC: 7093231. DOI: 10.1016/j.molcel.2020.01.009. View

17.

Gerlinger M, Santos C, Spencer-Dene B, Martinez P, Endesfelder D, Burrell R . Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol. 2012; 227(2):146-56. PMC: 3504091. DOI: 10.1002/path.4006. View

18.

Mazumdar J, Hickey M, Pant D, Durham A, Sweet-Cordero A, Vachani A . HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A. 2010; 107(32):14182-7. PMC: 2922515. DOI: 10.1073/pnas.1001296107. View

19.

Pathan M, Keerthikumar S, Ang C, Gangoda L, Quek C, Williamson N . FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics. 2015; 15(15):2597-601. DOI: 10.1002/pmic.201400515. View

20.

Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C . VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018; 361(6399):290-295. PMC: 6154478. DOI: 10.1126/science.aap8411. View